| Literature DB >> 25583815 |
.
Abstract
In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in BRCA1 or BRCA2. ©2014 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25583815 DOI： 10.1158/2159-8290.CD-NB2014-176
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397